R Shivakumar1, W Tan, G E Wilding, E S Wang, M Wetzler. 1. Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Abstract
BACKGROUND: Secondary acute lymphoblastic leukemia (sALL) is a rare disease and its biologic features are not well characterized. PATIENTS AND METHODS: We describe a cohort of seven patients and discuss 94 additional cases from the literature for whom biological parameters were described. Cases with incomplete data were excluded. RESULTS: Hodgkin's disease (HD) was more common in the 18-59 age group while breast and prostate cancers were prevalent only in the >or=18-year-old patients. The time interval to develop sALL was similar among all age groups but was significantly longer for HD and neuroblastoma primary diagnoses and sALL with complex karyotype. T-cell immunophenotype was more common in the <18 age group. Complete remission was infrequent in the >or=60 age group. The overall survival was poor for all sALL regardless of age, primary diagnoses, cytogenetic subgroups, or immunophenotype. Allogeneic transplantation most probably represents the only chance of cure. CONCLUSION: Better identification of prognostic factors to prevent the occurrence of sALL is indicated.
BACKGROUND: Secondary acute lymphoblastic leukemia (sALL) is a rare disease and its biologic features are not well characterized. PATIENTS AND METHODS: We describe a cohort of seven patients and discuss 94 additional cases from the literature for whom biological parameters were described. Cases with incomplete data were excluded. RESULTS:Hodgkin's disease (HD) was more common in the 18-59 age group while breast and prostate cancers were prevalent only in the >or=18-year-old patients. The time interval to develop sALL was similar among all age groups but was significantly longer for HD and neuroblastoma primary diagnoses and sALL with complex karyotype. T-cell immunophenotype was more common in the <18 age group. Complete remission was infrequent in the >or=60 age group. The overall survival was poor for all sALL regardless of age, primary diagnoses, cytogenetic subgroups, or immunophenotype. Allogeneic transplantation most probably represents the only chance of cure. CONCLUSION: Better identification of prognostic factors to prevent the occurrence of sALL is indicated.
Authors: Sonali M Smith; Michelle M Le Beau; Dezheng Huo; Theodore Karrison; Ronald M Sobecks; John Anastasi; James W Vardiman; Janet D Rowley; Richard A Larson Journal: Blood Date: 2003-03-06 Impact factor: 22.113
Authors: N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield Journal: J Clin Oncol Date: 1999-12 Impact factor: 44.544
Authors: M Wetzler; R K Dodge; K Mrózek; A J Carroll; R Tantravahi; A W Block; M J Pettenati; M M Le Beau; S R Frankel; C C Stewart; T P Szatrowski; C A Schiffer; R A Larson; C D Bloomfield Journal: Blood Date: 1999-06-01 Impact factor: 22.113
Authors: L Pagano; A Pulsoni; M E Tosti; L Annino; A Mele; A Camera; B Martino; C Guglielmi; R Cerri; E Di Bona; R Invernizzi; C Castagnola; R Bassan; L Mele; G Todeschini; G Leone; F Mandelli Journal: Br J Haematol Date: 1999-09 Impact factor: 6.998
Authors: E G Boerma; G W van Imhoff; I M Appel; N J G M Veeger; Ph M Kluin; J C Kluin-Nelemans Journal: Eur J Cancer Date: 2004-12 Impact factor: 9.162
Authors: William L Carroll; Deepa Bhojwani; Dong-Joon Min; Elizabeth Raetz; Mary Relling; Stella Davies; James R Downing; Cheryl L Willman; John C Reed Journal: Hematology Am Soc Hematol Educ Program Date: 2003
Authors: Guilin Tang; Zhuang Zuo; Deborah A Thomas; Pei Lin; Dingsheng Liu; Ying Hu; Hagop M Kantarjian; Carlos Bueso-Ramos; L Jeffrey Medeiros; Sa A Wang Journal: Haematologica Date: 2011-12-29 Impact factor: 9.941
Authors: Francesca Ferraro; Feng Gao; Keith Stockerl-Goldstein; Peter Westervelt; John F DiPersio; Armin Ghobadi Journal: Leuk Res Date: 2018-07-31 Impact factor: 3.156
Authors: Jane E Churpek; Rafael Marquez; Barbara Neistadt; Kimberly Claussen; Ming K Lee; Matthew M Churpek; Dezheng Huo; Howard Weiner; Mekhala Bannerjee; Lucy A Godley; Michelle M Le Beau; Colin C Pritchard; Tom Walsh; Mary-Claire King; Olufunmilayo I Olopade; Richard A Larson Journal: Cancer Date: 2015-12-07 Impact factor: 6.860
Authors: A S Rosenberg; A Brunson; J K Paulus; J Tuscano; T Wun; T H M Keegan; B A Jonas Journal: Blood Cancer J Date: 2017-09-08 Impact factor: 11.037